GlassScriptPhysician profile
Achraf Ali Makki
NPI 1205013471
$75,874.64
in general payments reported to CMS, 2019-2025
57 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $92.20 · 2021: $25K · 2022: $36K · 2023: $14K · 2024: $291 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,375 · Food and Beverage: $3,099 · Consulting Fee: $1,438 · Travel and Lodging: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,375.00 |
| Food and Beverage | $3,099.42 |
| Consulting Fee | $1,437.50 |
| Travel and Lodging | $568.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $65,499.57 | 2021-2025 | |
| Allergan, INC. | $1,801.11 | 2020-2021 | |
| Argenx US, INC. | $1,492.14 | 2023 | Vyvgart |
| Biogen, INC. | $397.42 | 2020-2024 | Vumerity, Spinraza, Tysabri |
| Jazz Pharmaceuticals INC. | $375.11 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $360.64 | 2021-2023 | |
| Lundbeck LLC | $349.35 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $302.40 | 2021-2024 | Amyvid, Emgality |
| Biohaven Pharmaceuticals, INC. | $300.19 | 2021 | |
| Pfizer INC. | $289.28 | 2021-2024 | |
| Ucb, INC. | $264.99 | 2021-2023 | Fintepla, Briviact |
| Abbott Laboratories | $221.51 | 2021-2023 | Proclaim |
| Genentech USA, INC. | $210.24 | 2022-2023 | Ocrevus |
| Sk Life Science, INC. | $207.92 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $206.36 | 2022-2023 | Ultomiris |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Achraf Makki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.